Health Economics›B-cell acute lymphoblastic leukemia pediatric›Consolidation after salvage therapy

Consolidation after salvage therapy

B-cell acute lymphoblastic leukemia pediatric · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Blinatumomab monotherapy Variant #05	—	R 728 965	56d	—	~7.7 mo	~1	~R 728 965 PFS proxy · indirect	2
Cyclophosphamide and TBI, then allo HSCT Variant #01 Partial	—	R 1 176	—	—	—	~1	~R 1 176 indirect	—

2 of 2 regimens shown